Eli Lilly is expanding its AI-driven discovery footprint through a multibillion-dollar expansion of its collaboration with Insilico Medicine. The updated deal structure is reported as $115 million upfront, with total potential consideration up to $2.75 billion across development, regulatory, and commercial milestones. At the same time, Lilly is pursuing a major neuroscience portfolio expansion via its Centessa buyout, targeting next-generation sleep-wake biology. Together, the two moves show Lilly stacking both platform capability (AI) and clinical-stage differentiation (orexin receptor 2 programs) to build momentum in CNS categories. For biotech, these transactions matter because they signal how big pharma is funding risk—using AI partnerships for pipeline options while using acquisitions to lock in clinical probability in specific therapeutic mechanisms.